Clinical Trial Update: Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating safety and immunogenicity of the Japanese Encephalitis vaccine IC51 (IXIARO) in a pediatric population; results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Japanese Encephalitis

Drugs mentioned

• IXIARO (inactivated Japanese encephalitis vaccine)

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Encephalitis | Phase 3 | Status: COMPLETED | Results posted: 2014-02-27